<DOC>
	<DOCNO>NCT00004237</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This randomized phase II trial study three regimen combination chemotherapy compare well work treat woman stage I stage II breast cancer .</brief_summary>
	<brief_title>Comparison Three Combination Chemotherapy Regimens Treating Women With Stage I Stage II Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy vinorelbine/epirubicin vinorelbine/mitoxantrone term clinical objective tumor response , clinical complete remission , pathological complete remission woman early stage breast cancer . - Compare efficacy 2 new regimen establish regimen cyclophosphamide/doxorubicin randomly select control group patient . - Compare toxicity side effect 2 new regimen patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord center age ( 50 vs 50 ) . Patients randomize one three treatment arm . - Arm I : Patients receive vinorelbine IV day 1 8 epirubicin IV day 1 . - Arm II : Patients receive vinorelbine IV day 1 8 mitoxantrone IV day 1 . - Arm III : Patients receive doxorubicin IV cyclophosphamide IV day 1 . Treatment continue every 3 week 6 course absence unacceptable toxicity disease progression . All patient except 50 whose tumor estrogen receptor negative receive oral adjuvant tamoxifen daily addition chemotherapy . All patient offer surgery follow completion chemotherapy . Radiotherapy begin within 4 week completion chemotherapy surgery , whichever immediately precede treatment . Patients follow every 3 month first 2 year , every 6 month next 3 year , annually thereafter . PROJECTED ACCRUAL : A total 62-125 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary breast cancer potentially operable Synchronous bilateral tumor eligible At least 3 cm maximum diameter Tumors least 2 cm eligible provide primary chemotherapy deem appropriate radical surgery would otherwise require No evidence metastatic disease No prior breast cancer Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 70 Sex : Female Menopausal status : Not specify Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 150,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Transaminases great 1.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No uncontrolled angina pectoris No heart failure No clinically significant uncontrolled cardiac arrhythmia LVEF least 50 % Other : Not pregnant nursing Fertile patient must use effective contraception No medical psychiatric condition impairs ability cope physically psychologically chemotherapy regimen No serious uncontrolled medical condition No prior malignancy except basal cell carcinoma skin carcinoma situ cervix PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
</DOC>